The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression
Open accessAbstract
Objective: Model-based meta-analysis was used to describe the time-course and dose-effect relationships of antidepressants and also simultaneously investigate the impact of various factors on drug efficacy. Methods: This study is a reanalysis of a published network meta-analysis. Only placebo-controlled trials were included in this study. The change rate in depression rating scale scores from baseline was used as an efficacy indicator because a continuous variable is more likely to reflect subtle differences in efficacy between drugs. Results: A total 230 studies containing 64 346 patients were included in the analysis. The results showed that the number of study sites (single or multi-center) and the type of setting (inpatient or noninpatient) are important factors affecting the efficacy of antidepressants. After deducting the placebo effect, the maximum pure drug efficacy value of inpatients was 18.4% higher than that of noninpatients, and maximum pure drug efficacy value of single-center trials was 10.2% higher than that of multi-central trials. Amitriptyline showed the highest drug efficacy. The remaining 18 antidepressants were comparable or had little difference. Within the approved dose range, no significant dose-response relationship was observed. However, the time-course relationship is obvious for all antidepressants. In terms of safety, with the exception of amitriptyline, the dropout rate due to adverse events of other drugs was not more than 10% higher than that of the placebo group. Conclusion: The number of study sites and the type of setting are significant impact factors for the efficacy of antidepressants. Except for amitriptyline, the other 18 antidepressants have little difference in efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“therapeutic response time generally takes weeks-to-months [3]”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 10×
“The Emax,drug,corrected of the remaining drugs were lower than 20%.”
BackgroundInfluentialCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100235 · Cited by 452
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Nguyen, T. H. T., Mouksassi, M., Holford, N., Al‐Huniti, N., Freedman, I., Hooker, A. C., John, J., Karlsson, M. O., Mould, D. R., Pérez Ruixo, J. J., et al. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12161 · Cited by 402
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?
Ioannidis, J. P. (2008) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-3-14 · Cited by 253 · cited 2×
“Currently, commonly used antidepressants include selective serotonin reuptake inhibitors (SSRIs) (Ioannidis, 2008), serotonin-norepinephrine reuptake inhibitors (Amick et al., 2015), selective norepinephrine reuptake inhibitors (Clayton et al., 2003), noradrenergic antagonist-specific serotonin…”
BackgroundNetwork Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants
Khoo, A. L., Zhou, H. J., Teng, M., Lin, L., Zhao, Y. J., Soh, L. B., Mok, Y. M., Lim, B. P., & Gwee, K. P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0267-6 · Cited by 228
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224 · cited 1×
“, 2003), noradrenergic antagonist-specific serotonin antagonists (Santarsieri and Schwartz, 2015), serotonin-modulating antidepressants, norepinephrine-dopamine reuptake inhibitors (Wang et al.”
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214
Jakubovski, E., Varigonda, A. L., Freemantle, N., Taylor, M. J., & Bloch, M. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030331 · Cited by 197
Amick, H. R., Gartlehner, G., Gaynes, B. N., Forneris, C., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Boland, E., Lux, L. J., Gaylord, S., et al. (2015) · BMJ · doi:10.1136/bmj.h6019 · Cited by 181
Does Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024886 · Cited by 151 · cited 1×
“Copyedited by: Cheng et al. | 83 A recently published meta-analysis (Munkholm et al., 2019) pointed out that the efficacy of antidepressants vs placebos was higher in trials with a placebo run-in study design compared with trials without such a design (P = .05); a lower efficacy was found in…”
ResultBaune, B. T., Brignone, M., & Larsen, K. G. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx070 · Cited by 140
Hieronymus, F., Nilsson, S., & Eriksson, E. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.104 · Cited by 100
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91 · cited 1×
“The World Health Organization states that the rates of depression have risen by more than 18% during the past decade, and it is predicted to be the leading cause of disease burden by 2030 (Deardorff and Grossberg, 2014; Papadimitropoulou et al., 2017).”
BackgroundClayton, A. H., Zajecka, J., Ferguson, J. M., Filipiak‐Reisner, J. K., Brown, M. T., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000066456.73432.09 · Cited by 89
Agomelatine for depression: expanding the horizons?
Norman, T. R., & Olver, J. S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574747 · Cited by 75
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., Tadić, A., & Lieb, K. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.07.003 · Cited by 73 · cited 1×
“There are many differences in the methodology of clinical trials of antidepressants (Wagner et al., 2017), such as having different control groups (positive drug or placebo control), different treatment durations, different number of study sites (single or multi-center), and so on.”
BackgroundAnsseau, M., von Frenckell, R., Mertens, C., Wilde, J. D., Botte, L., Devoitille, J.-M., Evrard, J.-L., Nayer, A. D., Darimont, P., Dejaiffe, G., et al. (1989) · Psychopharmacology · doi:10.1007/bf00444686 · Cited by 72
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
Wang, S., Han, C., Lee, S.-J., Jun, T., Patkar, A. A., Masand, P. S., & Pae, C. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.159 · Cited by 60
The Many Flavors of Model‐Based Meta‐Analysis: Part I—Introduction and Landmark Data
Boucher, M., & Bennetts, M. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12041 · Cited by 58
Deardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 50
Dose-response relationship of recent antidepressants in the short-term treatment of depression
Berney, P. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/pberney · Cited by 39
Tuma, J., Strubbe, J. H., STRUBBE, J. H., Mocaër, E., & Koolhaas, J. M. (2001) · Chronobiology International · doi:10.1081/cbi-100107514 · Cited by 27
Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
Won, E., Park, S., Han, K.-M., Sung, S.-H., Lee, H.-Y., Paik, J., Jeon, H. J., Lee, M., Shim, S.-H., Ko, Y., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.4.468 · Cited by 19
Maniadakis, N., Kourlaba, G., Mougiakos, T., Chatzimanolis, I., & Jönsson, L. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-173 · Cited by 18
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1311-5 · Cited by 14
Trazodone as a hypnotic in major depression
Becker, P. M. (2003) · Sleep Medicine · doi:10.1016/j.sleep.2003.08.007 · Cited by 10
An, G., Ohls, R. K., Christensen, R. D., Widness, J. A., Mock, D. M., & Veng‐Pedersen, P. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.02.001 · Cited by 8
Jakubovski, E., & Bloch, M. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16030304r · Cited by 2
Optimal dosing of antidepressant drugs – Authors' reply
Furukawa, T. A., Cowen, P. J., Salanti, G., Leucht, S., Egger, M., & Cipriani, A. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30339-6 · Cited by 1
Cited by
Hutton, T. M., Aaronson, S. T., Carpenter, L. L., Pages, K. P., Krantz, D., Lucas, L., Chen, B., & Sackeïm, H. A. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.10.001 · Cited by 80
Rupprecht, R., Wetzel, C. H., Dorostkar, M. M., Herms, J. W., Albert, N. L., Schwarzbach, J. V., Schumacher, M., & Neumann, I. D. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01561-3 · Cited by 73
Zhang, Y., Li, L., & Zhang, J. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13455 · Cited by 68
Self-citationDextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
McCarthy, B., Bunn, H., Santalucia, M., Wilmouth, C., Muzyk, A., & Smith, C. M. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1081 · Cited by 63
“Of those who do reach remission, patients often experience weeks-long delays prior to responding to treatment [3] and untoward side effects during this period from medications [7], highlighting the need for novel treatment options that are effective, rapid-acting, and well tolerated.”
BackgroundZhou, S., Li, P., Lv, X., Lai, X., Liu, Z., Zhou, J., Liu, F., Tao, Y., Zhang, M., Yu, X., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad177 · Cited by 48
Metadata
- Authors
- Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L.
- Affiliations
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Mental Health Center (CN)
- Corresponding author
- Zheng, Qingshan
- Li, Lujin
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-27
- Volume
- 23
- Issue
- 2
- Pages
- 76-87
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7094001
- OpenAlex
- W2989897972
- Cited by
- 38
- References
- 40
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 11 · 2023: 8 · 2022: 4 · 2021: 3 · 2020: 6
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Shanghai Municipal Health Planning Commission (2018YQ48)
- The Drug Innovation Major Project (2018ZX09734005-001-002, 2018ZX09734005-006, 2018ZX09711001-009-001, 2018ZX09731016, 2017ZX09304003)
- Science and Technology Innovation Action Plan of Shanghai (17401970900)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- antidepressants, major depressive disorder, acute depression, dose-response relationship, placebo effect, amitriptyline, inpatient vs outpatient treatment, antidepressant safety, adverse events
- MeSH terms
- Network Meta-Analysis, Network Meta-Analysis As Topic, Network Meta-Analysis as Topic, Acute Disease, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Models, Statistical, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.